Hikal Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Ashok Vishwanath Hiremath, was filed 29 Dec 2022.
Hikal Limited: what insiders have been doing
Hikal Limited belongs to the Health Care sector. Filings by its managers are published through SEBI (PIT + SAST). The last twelve months, up to 8 November 2026, brought 4 filings signed by 4 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (1,986 companies, median 4 filings), a count of 4 filings is typical. Looking back to 2022, when coverage begins, insiders filed 6 purchases and no sales.
Insider buying of Hikal Limited has been absent for the past year. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. This delay matters because a trade only becomes useful information once it is public.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Analyst consensus: bullish or bearish?
Analysts rate Hikal Limited Strong Buy (bullish), based on 1 analysts. Average price target: ₹300.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 30,231,914 shares@ ₹1.9967100.0% of flowEquity SharesSEBI:df9e21c3a55ffca19b08eeb3569175de2400fb64
- 10,253,302 shares@ ₹2.00100.0% of flowEquity SharesSEBI:6b9465277dcd1533df066afcfda96478d182b3ac
- 19,978,612 shares@ ₹2.00100.0% of flowEquity SharesSEBI:75bd7f1f6d62cd9c731d3ee94bb0f6fa975202e5
- 30,231,914 shares@ ₹1.9967100.0% of flowEquity SharesSEBI:e966c29dc480398a2cac444f7d896a7af1abd078
- 28,540 shares@ ₹359.061528.9% of flowEquity SharesSEBI:d77cb400c1e9ce44c3f0ee57342423cbfce8fbbeCanonical exit: 29 Mar 2023 (T+90)
- 5,600 shares@ ₹354.46755.6% of flowEquity SharesSEBI:26580b8d0fda21623c63ff4006fa5e88b97cf844Canonical exit: 28 Mar 2023 (T+90)
- 12,622 shares@ ₹354.369812.6% of flowEquity SharesSEBI:2faf748f7cc9ae8ad58d65b4f0575617099d98e6Canonical exit: 27 Mar 2023 (T+90)
- 9,813 shares@ ₹348.53079.6% of flowEquity SharesSEBI:9c4b64858a7ddd654ba3c179ba47958ca7cd1c6dCanonical exit: 26 Mar 2023 (T+90)
- 28,425 shares@ ₹351.568328.2% of flowEquity SharesSEBI:0449bc827f69ccbc2ca978cfafe22910ae06cc56Canonical exit: 23 Mar 2023 (T+90)
- 15,000 shares@ ₹354.876215.0% of flowEquity SharesSEBI:9748e4072446120a0e51f9cec181435eba617482Canonical exit: 22 Mar 2023 (T+90)
10 of 10 declarations
About Hikal Limited
Hikal Limited is a company operating in the healthcare and pharmaceutical sector, specializing in the manufacturing of chemicals and pharmaceuticals. It is listed on the XBOM market.
